Recent studies indicated that the activating mutation of the KEAP1–NRF2 pathway induces radioresistance, and KEAP1/NRF2 mutation status is a strong predictor of RT outcome in patients with NSCLC [11]. The gene discussed is KEAP1; the disease is non-small cell lung carcinoma.